• Users Online: 2262
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2021  |  Volume : 10  |  Issue : 1  |  Page : 8-12

Evaluation of chemerin in acute coronary syndrome and its role in cardiodiabetics


1 Department of Pathology, M.L.N. Medical College and Associated S.R.N Hospital, Prayagraj, Uttar Pradesh, India
2 Cardiology, M.L.N. Medical College and Associated S.R.N Hospital, Prayagraj, Uttar Pradesh, India

Correspondence Address:
Dr. Anshul Singh
Department of Pathology, M.L.N. Medical College and Associated S.R.N Hospital, George Town, Prayagraj - 211 001, Uttar Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/JCPC.JCPC_45_20

Rights and Permissions

Objectives: Chemerin is a proinflammatory adipokine whose role in metabolic syndrome and insulin resistance is well known. Chemerin has shown to carry a good prognostic/predictive value in patients of Coronary Artery Diseases (both chronic as well as acute) in the studies done in the US and Europe. However, no such study has been reported from India. Hence, this study was undertaken to evaluate Chemerin in patients of Acute Coronary Syndrome (ACS) and assess their role in cardiodiabetic patients. Materials and Methods: We included seventy cases of ACS and further subdivided them into two groups - (1) with co-existing diabetes mellitus (ACS-DM) (n = 33) and (2) without co-existing DM (ACS-NDM) (n = 37). Thirty healthy age and sex matched controls were included for comparison. Chemerin levels were measured by ELISA, hs C Reactive Protein (hs CRP) by turbidimetric assay, Creatine Kinase MB (CK-MB) by immunoinhibition (IFCC method) and Troponin I (Trop I) by Chemiluminescent Microparticle immunoassay. All the data were analyzed using Social Science Statistics Calculators. Results: Serum Chemerin levels were highest in ACS-DM (0.80 ± 0.61 ng/ml) as compared to ACS-NDM (0.42 ± 0.22 ng/ml) and controls (0.25 ± 0.10 ng/ml). On comparison, the difference amongst all was statistically significant. Furthermore, Chemerin showed a positive correlation with all the three parameters of ACS – hs CRP, CK- MB and Trop I. Conclusion: Chemerin levels are markedly elevated in ACS patients, more so in those with coexisting diabetes [cardio diabetics]. Chemerin is a novel biomarker of ACS.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed284    
    Printed0    
    Emailed0    
    PDF Downloaded38    
    Comments [Add]    

Recommend this journal